Basel, Switzerland, and Moscow, Russia, October 14, 2009 - Roche, Switzerland, and Viriom Ltd., Member of The Center for Innovative Technologies ChemRar, Russia, have signed a licence agreement granting Viriom development and commercialization rights for potential novel treatments for HIV/AIDS patients in Russia, Ukraine, Belarus and Kazakhstan.
Under the terms of the agreement, Roche will provide Viriom with pre-clinical candidates belonging to the new class of non-nucleoside inhibitors of reverse transcriptase (NNRTI). Roche has also agreed to contribute its significant expertise in the HIV field through scientific coaching and representation on Viriom’s Board of Directors. Royalties from the resulting sales in Russia, Ukraine, Belarus and Kazakhstan will be paid to Roche, and it will also retain its rights in all other territories. Viriom, in turn, will be receiving dividents from the global commercialization of the novel treatments.
Viriom Ltd. will be developing these innovative compounds in Russia, including pre-clinical research and initiation of clinical studies which are expected to begin in 2010.
“This agreement will bring differentiated medicines to HIV patients in countries with high disease prevalence. It is a pioneering partnership with a young Russian company, in line with PHARMA-2020, a significant state initiative aimed at accelerating development of the Russian pharmaceutical industry. This represents a completely new concept for Russia”, said Milos Petrovic, General Manager of Roche Moscow Ltd. and Head of Roche Representative Office in Russia.
Tuygan Goeker, Regional Head for CEMAI (Central & Eastern Europe, Middle East, Africa, Indian sub-continent) added, “Our partnership with Viriom exemplifies Roche’s innovation strategy in growing markets like Russia. The compounds licensed to Viriom will help to create a Russian BioCluster/Incubator. Roche will continue to look for innovative products and creative partnerships for emerging markets that will strengthen our efforts to make differentiated medicines available to the patients who need them.”
“We are honoured that Roche has chosen our company as a partner for development of a new HIV treatment," said Andrey Ivashchenko, General Manager of Viriom. "Roche’s expertise in the HIV field and in global drug development only increases the potential of this partnership, which aims at discovering new approaches for fighting against AIDS.”
For further information, please contact:
Irina Tyrnova, COO
Rabochaya 2a/1, Khimki
Moscow, Russia 141400
Roche Pharma Partnering
Phone: +41 61 688 3408